The role of surgery in bone metastases of renal cell carcinoma: 13 cases report;La place de la chirurgie des métastases osseuses dans le cancer du rein : à propos de 13 cas

Progres en Urologie

Volumn 18, Issue 13, 2008, Pages 1045-1049

  Le Mouel, S ^a   Gaston, A ^a   Paule, B ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Osseous metastases; Renal cell carcinoma; Surgery

Indexed keywords

ARTICLE; BONE TUMOR; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEASIBILITY STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 56649105207     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2008.08.004     Document Type: Article

References (19)

1. Martel C.L., and Lara P.N. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 45 (2003) 177-190
2. Flanigan R.C., Campbell S.C., Clark J.I., and Picken M.M. Metastatic renal cell carcinoma. Curr Treat Options Oncol 4 (2003) 385-390
3. Zekri J., Ahmed N., Coleman R.E., and Hancock B.W. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19 (2001) 379-382
4. Paule B. Interleukine-6 et cancer du rein métastatique : bases moléculaires et implications thérapeutiques. Prog Urol 11 (2000) 368-375
5. Althausen P., Althausen A., Jennings L.C., and Mankin H.J. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80 (1997) 1103-1109
6. Dekernion J.B., Ramming K.P., and Smith R.B. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120 (1978) 148-152
7. Kwak C., Park Y.H., Jeong C.W., Lee S.E., and Ku J.H. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Urol Int 79 (2007) 145-151
8. Lin P.P., Mirza A.N., Lewis V.O., Cannon C.P., Tu S.M., Tannir N.M., et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89 (2007) 1794-1801
9. Smith E.M., Kursh E.D., Makley J., and Resnick M.I. Treatment of osseous metastases secondary to renal cell carcinoma. J Urol 148 (1992) 784-787
10. van der Poel H.G., Roukema J.A., Horenblas S., van Geel A.N., and Debruyne F.M. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35 (1999) 197-203
11. Kim B., and Louie A.C. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127 (1992) 1343-1349
12. Sherry R.M., Pass H.I., Rosenberg S.A., and Yang J.C. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69 (1992) 1850-1855
13. Vogl U.M., Zehetgruber H., Dominkus M., Hejna M., Zielinski C.C., Haitel A., et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95 (2006) 691-698
14. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 8 (1999) 2530-2540
15. Motzer R.J., Michaelson M.D., Rosenberg J., Bukowski R.M., Curti B.D., George D.J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178 (2007) 1883-1887
16. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
17. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
18. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
19. Saad F., and Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96 (2005) 964-969